Detailed Result for NCT00002318

NCT ID: NCT00002318
NLM Download Date Description: N/A
Study First Submitted Date: 1999-11-02
Last Update Submitted Date: 2005-06-23
Last Update Submitted Date: 2005-06-23
Result First Submitted Date: N/A
Disposition First Submitted Date: N/A
Start Month Year: N/A
Start Date: N/A
Start Date Type: N/A
Verification Month Year: January 1996
Verification Date: 1996-01-31
Completion Month Year: N/A
Completion Date: N/A
Completion Date Type: N/A
Primary Completion Month Year: N/A
Primary Completion Date: N/A
Primary Completion Date Type: N/A
Study first Submitted QC Date: 2001-08-30
Study first posted Date: 2001-08-31
Result first Submitted QC Date: N/A
Result First Posted Date: N/A
Disposition First Submitted QC Date: N/A
Disposition First Posted Date: N/A
Last Updated Submitted QC Date: 2005-06-23
Last Updated Posted Date: 2005-06-24
Target Duration: N/A
Study Type: Interventional
Acronym: N/A
Baseline Population: N/A
Brief Title: A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma
Official Title: Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma
Overall Status: Unknown status
Last Known Status: Active, not recruiting
Phase: Phase 3
Enrollment: 225
Enrollment Type: N/A
Source: NIH AIDS Clinical Trials Information Service
Limitation and Caveats: N/A
Number of Arms: N/A
Number of Groups: N/A
Why Stopped: N/A
Has Expanded Access: N/A
Expanded Access Type Individual: N/A
Expanded Access Type Intermediate: N/A
Expanded Access Type Treatment: N/A
Has DMC: N/A
Is it FDA Regulated Drug: N/A
Is it FDA Regulated Device: N/A
Is it Unapproved Device: N/A
Is PPSD: N/A
Is US Export: N/A
Is Biospec Retention: N/A
Biospec Description: N/A
Plan to Share IPD: N/A
Plan to Share IPD Description: N/A
IPD Time Frame: N/A
IPD Access Criteria: N/A
IPD URL: N/A
© 2023 MedicalDeviceHub, LLC